Immuneering Corporation Debt Securities, Available-for-sale, Amortized Cost, Current
Immuneering Corporation (IMRX) had Debt Securities, Available-for-sale, Amortized Cost, Current of $5.45 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Credit Loss, Additional Improvements
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2025-03-20
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $5.45M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $4.99M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $26.26M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $32.92M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2024-09-30 | $5.45M 10-Q · filed 2024-11-13 |
| 2024-03-31 | $4.99M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $26.26M 10-K · filed 2025-03-20 |
| 2022-12-31 | $32.92M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |